In addition, the treatment with anti PCSK9 monoclonal antibodies reduces CCR2 expression and the migratory capacity of circulating monocytes in familial hypercholesterolaemia (FH) patients28. The gene discussed is PCSK9; the disease is familial hyperaldosteronism.